Skip to content

Ketamine: all studies

Page 417 of 449: studies 4,161 to 4,170 of 4,486, newest first. Back to the ketamine overview

Research

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Expert Review of Clinical Pharmacology June 1, 2020 Kyle T. Greenway, Nicolas Garel, Lisa Jerome et al. 87 citations

INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind...

Ayahuasca – potential therapeutic properties in psychiatry. Research review

Psychiatria Polska April 30, 2020 Aleksandra Barabasz-Gembczyk, Krzysztof Kucia 4 citations

Ayahuaska, zwana również „lianą duszy”, „pnączem duszy” to rytualny psychodelik podawany tradycyjnie w formie wywaru roślinnego, od stuleci stosowany przez rdzenną ludność Ameryki Południowej, a w ostatnich 25 latach również w krajach Europy, Azji, Afryki, Australii, w Kanadzie i Stanach Zjednoczonych Ameryki Północnej. Jej aktywność biologiczna wynika z zawartości N,N- dimetrylotryptaminy...

Designer drugs: mechanism of action and adverse effects

Archives of Toxicology April 1, 2020 Dino Luethi, Matthias E. Liechti 258 citations

Abstract Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer...

DOI: 10.1007/s00204-020-02693-7 (opens in new tab) Full text (opens in new tab) Pharmacology Designer drug Mechanism of action Adverse effect +6

Can Psychedelics Radically Change SUD Treatment?

Psychiatric News March 20, 2020 Katie O’connor

Though the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research persist. Researchers around the world are investigating how drugs such as LSD, MDMA (also known as ecstasy), ketamine, and psilocybin (the active ingredient in magic mushrooms) can treat patients with substance use disorders (SUD). Though there is still a lot to learn, early...

Reviewing the Potential of Psychedelics for the Treatment of PTSD

The International Journal of Neuropsychopharmacology March 12, 2020 Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema et al. 262 citations

Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs...

City Checking: Piloting the UK's first community-based drug safety testing ('drug checking') service in two city centres.

British Journal of Clinical Pharmacology February 6, 2020 Fiona Measham

AIMS To explore the feasibility of delivering community-based drug safety testing ('drug checking'), to trial service design characteristics and to compare with festival-based testing. METHODS 171 substances of concern were submitted on five dates at three venues in two UK cities and tested using up to six analytical techniques. Test results and harm reduction advice were distributed directly...

Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.

Journal of Medicinal Chemistry January 24, 2020 Lee E. Dunlap, Arya Azinfar, Calvin Ly et al.

Ketamine, N,N-dimethyltryptamine (DMT), and other psychoplastogens possess enormous potential as neurotherapeutics due to their ability to potently promote neuronal growth. Here, we report the first-ever structure-activity relationship study with the explicit goal of identifying novel psychoplastogens. We have discovered several key features of the psychoplastogenic pharmacophore and used this...

Management of Treatment-Resistant Depression: Challenges and Strategies

Neuropsychiatric Disease and Treatment 2020 Daphne Voineskos, Zafiris J Daskalakis, Daniel M. Blumberger 430 citations

Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder which does not respond to traditional and first-line therapeutic options. There are several definitions and staging models of TRD and a consensus for each has not yet been established. However, in common for each model is the inadequate response to at least 2 trials of antidepressant pharmacotherapy. In this review, a...

Decreased directed functional connectivity in the psychedelic state.

Neuroimage December 17, 2019 Lionel Barnett, Suresh Muthukumaraswamy, Robin Carhart-Harris et al. 88 citations

Neuroimaging studies of the psychedelic state offer a unique window onto the neural basis of conscious perception and selfhood. Despite well understood pharmacological mechanisms of action, the large-scale changes in neural dynamics induced by psychedelic compounds remain poorly understood. Using source-localised, steady-state MEG recordings, we describe changes in functional connectivity...

DOI: 10.1016/j.neuroimage.2019.116462 (opens in new tab) Full text (opens in new tab) Psychedelics psychedelic states Substances Brain communication Information flow +11

Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants

European Journal of Neuroscience December 6, 2019 Ronald S. Duman, Satoshi Deyama, Manoela V. Fogaça 319 citations

The pathophysiology and treatment of depression have been the focus of intense research and while there is much that remains unknown, modern neurobiological approaches are making progress. This work demonstrates that stress and depression are associated with atrophy of neurons and reduced synaptic connectivity in brain regions such as the hippocampus and prefrontal cortex that contribute to...